#### Online Resource 2

Journal: Pharmaceutical Research

Title: Application of pharmacokinetic-pharmacodynamic modeling to inform translation of in vitro NaV1.7

inhibition to in vivo pharmacological response in non-human primate

Authors: Jeanine E. Ballard<sup>1</sup>, Parul Pall<sup>2</sup>, Joshua Vardigan<sup>2</sup>, Fuqiang Zhao<sup>3</sup>, Marie A. Holahan<sup>3</sup>, Richard Kraus<sup>4</sup>,

Yuxing Li<sup>4</sup>, Darrell Henze<sup>5</sup>, Andrea Houghton<sup>5</sup>, Christopher S. Burgey<sup>6</sup>, Christopher Gibson<sup>1</sup>

Affiliations: Merck & Co., Inc., Kenilworth, NJ USA

<sup>1</sup> Pharmacokinetics, Pharmacodynamics, and Drug Metabolism

<sup>2</sup> In Vivo Neuropharmacology

<sup>3</sup> MR-CT-US & Optical Imaging

<sup>4</sup> Neuronal Signaling

<sup>5</sup> Quantitative Biosciences


<sup>6</sup> Discovery Chemistry

Corresponding author: Jeanine E. Ballard

jeanine ballard@merck.com


1

Supplementary Figure S4. Visual predictive check of model predicted versus observed plasma concentration over time for each compound in satellite PK studies




Supplementary Figure S5. Visual predictive check of simulated versus observed plasma concentration over time for each compound in fMRI PK studies

## (a) Compounds with acceptable simulation of IV infusion PK profile




## (b) Compounds with unacceptable simulation of IV infusion PK profile




Supplementary Figure S6. Visual predictive check of effect compartment PK-PD model predicted versus observed percent inhibition of fMRI signal over time for each compound with washout data in the fMRI assay


## Compound 6




## Compound 13




### Compound 14




## Compound 16




## Compound 18




# Compound 21




# Compound 22



Compound 24



# Compound 25



# Compound 27

